SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

10796	Companies
233362	Keywords
162037	Articles
124561	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 09/11/2025 at 07:00, 10 months 22 days ago

Communiqué de presse : Le SAR402663 de Sanofi a obtenu la désignation « fast track » aux États-Unis pour le traitement de la dégénérescence maculaire liée à l’âge néovasculaire
Sanofi obtient la dÃ©signation 'fast track' pour le traitement de la DMLA nÃ©ovasculaire aux Etats-Unis. ThÃ©rapie gÃ©nique innovante pour rÃ©duire la perte de vision

Sanofi DÃ©signation Fast Track DMLA NÃ©ovasculaire ThÃ©rapie GÃ©nique Perte De Vision
BRIEF

published on 08/29/2025 at 23:55, 11 months 4 days ago

Wayrilz de Sanofi obtient l'approbation de la FDA comme premier inhibiteur de BTK pour le traitement du PTI

Approbation De La FDA Sanofi Wayrilz Inhibiteur De BTK Thrombocytopénie Immunitaire
BRIEF

published on 08/29/2025 at 23:55, 11 months 4 days ago

Sanofi’s Wayrilz Gets FDA Approval as First BTK Inhibitor for ITP

FDA Approval Sanofi BTK Inhibitor Wayrilz Immune Thrombocytopenia
PRESS RELEASE

published on 08/29/2025 at 23:50, 11 months 4 days ago

Communiqué de presse : Wayrilz de Sanofi est approuvé aux États-Unis comme premier inhibiteur de BTK pour la thrombocytopénie immune
Wayrilz de Sanofi, premier inhibiteur de BTK pour la thrombocytopénie immune, approuvé aux États-Unis par la FDA. Étude LUNA 3 a montré une réponse plaquettaire rapide et durable pour les patients adultes

FDA Sanofi Wayrilz Inhibiteur BTK Thrombocytopénie Immune
PRESS RELEASE

published on 08/29/2025 at 23:50, 11 months 4 days ago

Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
Sanofi's Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia. Novel treatment targets BTK through multi-immune modulation to address root causes of ITP, providing rapid and durable platelet response and improved symptoms

Sanofi BTK Inhibitor Wayrilz Immune Thrombocytopenia LUNA 3 Study
PRESS RELEASE

published on 08/25/2025 at 18:30, 11 months 9 days ago

Sanofi: Disclosure of trading in own shares
BRIEF

published on 08/18/2025 at 18:35, 11 months 16 days ago

Sanofi Reports Total Shares and Voting Rights for July 2025

Voting Rights French Commercial Code Shares 2025 Sanofi
BRIEF

published on 08/18/2025 at 18:35, 11 months 16 days ago

Sanofi publie le nombre total d'actions et de droits de vote pour juillet 2025

Actions Droit De Vote 2025 Sanofi Code De Commerce Français
PRESS RELEASE

published on 08/18/2025 at 18:30, 11 months 16 days ago

Sanofi: Information concerning the total number of voting rights and shares - July 2025
Sanofi discloses total voting rights and issued shares as per French commercial and stock market regulations. Details available on their website

Voting Rights Shares French Regulations Investor Relations Sanofi
BRIEF

published on 08/14/2025 at 07:05, 11 months 20 days ago

Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin dans l’UE

Sanofi EMA Médicament Orphelin Rilzabrutinib Maladie IgG4

Accesswire

Published on 08/03/2026 at 23:00, 29 minutes ago

Viemed Healthcare Announces Second Quarter 2026 Financial Results
Published on 08/01/2026 at 01:58, 2 days 21 hours ago

Clôture de l'option sur la propriété de graphite au Québec
Published on 08/01/2026 at 01:20, 2 days 22 hours ago

Gamma Resources Announces $880,000 Private Placement with Full Warrant Coverage
Published on 08/01/2026 at 01:15, 2 days 22 hours ago

Clean Air Metals and Fiore-Backed Springbok Ventures Announce Strategic Business Combination
Published on 08/01/2026 at 00:30, 2 days 22 hours ago

Battery X Metals Announces Amendment to Corporate Awareness Engagement

View all ACCESSWIRE

EQS Group

Published on 08/03/2026 at 21:39, 1 hour 50 minutes ago

PAUL Tech AG reports net income after tax of EUR 3.2 million for fiscal year 2025 and issues a positive outlook for fiscal year 2026
Published on 08/03/2026 at 19:35, 3 hours 54 minutes ago

Enzene Launches NeX™, a Comprehensive Suite of Solutionsto Enable Cost-Efficient, High-Yielding Local Biomanufacturing
Published on 08/03/2026 at 19:01, 4 hours 28 minutes ago

EQS-Adhoc: Fresenius Medical Care AG : Fresenius Medical Care reports operating income excluding special items to be above market expectations in Q2 2026 and confirms its outlook for the financial year 2026
Published on 08/03/2026 at 19:00, 4 hours 29 minutes ago

PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 27 JUILLET 2026 au 31 JUILLET 2026
Published on 08/03/2026 at 19:00, 4 hours 29 minutes ago

PATRIMOINE ET COMMERCE: INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF

Les Echos

Published on 08/03/2026 at 18:45, 4 hours 44 minutes ago

Covivio - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
Published on 08/03/2026 at 18:45, 4 hours 44 minutes ago

Covivio - Information on total number of voting rights and share capital
Published on 08/03/2026 at 18:35, 4 hours 54 minutes ago

Covivio Hotels - Informations relatives au nombre total de droits de vote et d'actions composant le capital social
Published on 08/03/2026 at 18:14, 5 hours 14 minutes ago

Évolution mensuelle du 31 juillet 2026
Published on 08/03/2026 at 18:00, 5 hours 29 minutes ago

H1 2026 revenue

View all LES ECHOS COMFI WIRE